Pfizer: Potential cachexia cancer drug shows life-saving promise
A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drug-maker Pfizer announced Saturday.
Drug breakthrough provides new hope for cancer patients with cachexia
Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and muscle wasting.
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of change from baseline in body weight compared to placebo in people with cancer cachexia and elevated levels of GDF-15.
Pfizer Drug Helped Cancer Patients Regain Weight, Study Shows
Pfizer Inc.’s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, offering fresh promise for treating the dangerous muscle-wasting condition.
Pfizer says its experimental drug for deadly condition that causes appetite and weight loss in cancer patients shows positive trial results
The results could pave the way for Pfizer's drug ponsegromab to become the first-ever approved treatment specifically for cancer cachexia.
Pfizer therapy succeeds in mid-stage trial for cancer-related weight loss
Pfizer's (PFE) experimental therapy for cancer related weight loss, ponsegromab, meets the primary endpoint in Phase 2 trial. Read more here.
Pfizer drug shows promise in cancer-related condition that causes weight loss and weakness
Pfizer reported at #ESMO that an experimental antibody helped cancer patients with a condition known as cachexia.
Science Daily1d
New cancer cachexia treatment boosts weight gain and patient activity
A nationwide clinical trial shows positive results for cancer patients with this common wasting syndrome. Researchers discovered a drug that safely and effectively helped cancer patients when they ...
The Pharma Letter5d
ESMO 2024: Positive Phase II results for Pfizer’s ponsegromab in cancer cachexia
The Phase II study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its ...
Optimistic Buy Rating for Artelo Biosciences Amidst Growing Focus on Cancer Cachexia Therapies
Maxim Group analyst Jason McCarthy maintained a Buy rating on Artelo Biosciences (ARTL – Research Report) yesterday and set a price ...
KOIN Portland on MSN15h
New OHSU study shows promise in treating ‘urgent, unmet need’ in cancer patients
A new study from OHSU is claiming to show promise in the treatment of what they are calling an "urgent, unmet need" in cancer ...
VegNews12h
Eating More Plants Can Delay “Age Bursts” in Your 40s and 60s
Aging might not occur as gradually as we previously thought, with research pointing to two “age bursts” at 44 and 60. Here is ...
BioPharma Dive4d
ESMO24: A cancer cachexia drug, VEGF enthusiasm and immunotherapy’s survival impact
Results for Pfizer’s ponsegromab looked promising, while BioNTech and Instil Bio capitalized on momentum surrounding a kind of bispecific antibody.
Pfizer : Phase 2 Study Of Ponsegromab In Cancer Cachexia Meets Primary Endpoint
Pfizer Inc. (PFE) said Saturday that its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation ...
Pharmaceutical Technology22d
Cachexia drugs in development, 2024
GlobalData tracks 24 drugs in development for Cachexia by 20 companies/universities/institutes. The top development phase for Cachexia is preclinical, with 13 drugs in that stage.
Medpage Today on MSN3d
Novel Agent Effective for Cancer Wasting Disorder
Patients with cancer cachexia and an elevated level of growth differentiation factor 15 (GDF-15) achieved significant ...